<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943029</url>
  </required_header>
  <id_info>
    <org_study_id>NEOSUN</org_study_id>
    <nct_id>NCT04943029</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC</brief_title>
  <acronym>NEOSUN</acronym>
  <official_title>Induction Therapy With Chemoimmunotherapy Followed by Surgery for Unresectable Stage III Non-small Cell Lung Cancer: a Single-center, Single-arm, Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Camrelizumab in&#xD;
      combination with platinum doublet neoadjuvant chemotherapy before surgery [neoadjuvant&#xD;
      phase], followed by Camrelizumab alone after surgery [adjuvant phase] in participants with&#xD;
      unresectable stage III non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concurrent chemoradiotherapy is the recommended therapeutic approach for patients with&#xD;
      unresectable stage III non-small cell lung cancer(NSCLC), although surgery offers the chance&#xD;
      of cure. With combined radiation and chemotherapy, the prognosis of unresectable stage III&#xD;
      NSCLC remains poor. Immunotherapy combined with chemotherapy has been shown to be efficacious&#xD;
      as treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) without targetable&#xD;
      genetic aberrations. Camrelizumab, a humanised monoclonal antibody against PD-1, has shown&#xD;
      its efficacy in the treatment of advanced NSCLC. This study is to studying neoadjuvant&#xD;
      camrelizumab plus double platinum based chemotherapy followed by surgery to see how well it&#xD;
      works in treating patients with unresectable stage III NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathological response (MPR) rate</measure>
    <time_frame>1 year</time_frame>
    <description>MPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and all resected lymph nodes following completion of neoadjuvant therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resectability rate</measure>
    <time_frame>1 year</time_frame>
    <description>Resectability rate is defined as the percentage of patients who were able to undergo surgery after neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of incidence of adverse Events</measure>
    <time_frame>approximately 16.5 months overall</time_frame>
    <description>The incidences and types of adverse events that occur during neoadjuvant therapy and perioperative period (within postoperative 30 days and 90 days) will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>2 year</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>2 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>PD-1+Chemo+surgery+PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive neoadjuvant Carrelizumab plus double platinum based chemotherapy for 3 cycles, followed by surgical resection and adjuvant Carrelizumab for 16 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carrelizumab</intervention_name>
    <description>Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.</description>
    <arm_group_label>PD-1+Chemo+surgery+PD-1</arm_group_label>
    <other_name>PD-1 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)</intervention_name>
    <description>Nab-paclitaxel: 260mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m^2, IV, day 1 of each 21-day cycle, 3 cycles.</description>
    <arm_group_label>PD-1+Chemo+surgery+PD-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.</description>
    <arm_group_label>PD-1+Chemo+surgery+PD-1</arm_group_label>
    <other_name>chemotherapeutic drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery must be done within the 4th-6th week from day 1 cycle 3 of neoadjuvant treatment (4-6 weeks after day 1 of cycle 3)</description>
    <arm_group_label>PD-1+Chemo+surgery+PD-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent provided.&#xD;
&#xD;
          -  Age 18-70 when signing the consent form, both male and female;&#xD;
&#xD;
          -  The ECOG score is 0 or 1;&#xD;
&#xD;
          -  Unresectable stage III non-small cell lung cancer confirmed by histopathology or&#xD;
             cytology（III A-bulky N2, III B，IIIC）;&#xD;
&#xD;
          -  Adequate hematological function, liver function and renal function;&#xD;
&#xD;
          -  Female participants should not be pregnant or breast-feeding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  EGFR mutation or ALK mutation was positive;&#xD;
&#xD;
          -  Previously received systemic anti-tumor therapy for non-small cell lung cancer;&#xD;
&#xD;
          -  Subjects who have received chest radiotherapy in the past;&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,&#xD;
             unstable angina, congestive heart failure, myocardial infarction within the previous&#xD;
             year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic&#xD;
             disease);&#xD;
&#xD;
          -  Pregnancy or breast-feeding women;&#xD;
&#xD;
          -  Ingredients mixed with small cell lung cancer patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongde Liao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan Union Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongde Liao, PhD</last_name>
    <phone>+86 15972212919</phone>
    <email>liaotjxw@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mingliang Wang, MD</last_name>
    <phone>+86 15927066167</phone>
    <email>wml6667@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingliang Wang, MD</last_name>
      <phone>+86 15927066167</phone>
      <email>wml6667@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable</keyword>
  <keyword>Stage Ⅲ NSCLC</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>chemoimmunotherapy</keyword>
  <keyword>camerlizumab</keyword>
  <keyword>PD-1</keyword>
  <keyword>sugery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

